Drug Trial Radar · NCT02809131
Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
Last checked: Nov 19, 2026Latest source record: May 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,010
Actual
Start
Apr 1, 2016
Primary completion
Mar 31, 2021
Study completion Sep 30, 2021
Sponsor
- Lead sponsor
- Vanderbilt University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Thomas Jefferson University; Cooper Norcross Health; Valley Health System; Medtronic
- First posted
- Jun 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The number of cardiac implantable electronic devices (CIEDs) implanted each year has grown rapidly over the past two decades. CIED infections, defined as infections involving the generator implant site (pocket) and/or intravascular leads, have become increasingly prevalent, with the rate of growth in infections outpacing that of CIED procedures. The odds of both short term and long term mortality are at least doubled in patients who suffer CIED infections, and long term survival is particularly poor in women. Optimal strategies to prevent CIED infections in high-risk patients are largely unproven. However, recent observational studies of an antibiotic-coated envelope implanted at the time of CIED procedure have shown that this strategy is associated with a low incidence of CIED infections. Other interventions to prevent CIED infections, including the use of antibiotic irrigant used to wash the pocket during implantation and postoperative oral antibiotics, are commonly used but not supported by rigorous controlled studies. The Specific Aim of this study is to test the hypothesis that the use of the antibacterial envelope alone is noninferior to a strategy using the antibacterial envelope and intraoperative antibacterial irrigant and postoperative oral antibiotics for the reduction of cardiac implantable device infections in patients with ≥2 risk factors for infection.
Conditions
- Sick Sinus Syndrome
- Complete Heart Block
- Syncope
- Chronic Systolic Heart Failure
Interventions
polymixin/bacitracinDrug
Antibacterial irrigation
cephalexin, or levofloxacin, or clindamycinDrug
Post operative oral antibiotics
SalineDrug
Saline irrigation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) InfectionTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University Medical Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.